СОВЕРШЕНСТВОВАНИЕ МЕТОДОВ ЛЕЧЕНИЯ КОРОНАВИРУСНОЙ ИНФЕКЦИИ COVID-19
Ключевые слова:
koronavirus, PCR testi, Ganoderma lucidum, Alxadaya, II turdagi alveolotsitlar, SARS-CoV-2, o‘tkir nafas yetishmasligi sindromi.Аннотация
Maqsad: Ganoderma lucidum va Alxadai asosidagi yangi preparatning COVID-19 keltirib chiqaradigan koronavirus infeksiyasi jarayoniga ta'sirini baholash. Material va usullar: tadqiqot randomizatsiyalangan, ikki marta ko'r, platsebo- nazorat qilingan. Tajribalar vazni 220-250 g bo‘lgan har ikki jinsdagi 100 ta etuk kalamushlarda o‘tkazildi.Hayvonlar oziq-ovqat va suvdan erkin foydalanish mumkin bo‘lgan, kun va tun tabiiy o‘zgarib turadigan vivariyda saqlangan. Tajribalar o'z-o'zidan nafas olish va atrof-muhit harorati 24-25°С sharoitida amalga oshirildi. Virus izolyatsiyasi virusli hujayra madaniyatida klinik materialning virusli namunasidan (nazofarengeal tampon) amalga oshirildi. Natijalar: PCR diagnostikasini o'tkazishda 5-6 kunlarda kalamushlarning qonida 110 nusxa/ml topildi, bu nafas olish yo'llarida virusning yuqori darajasini ko'rsatadi. Virusli RNKni aniqlash darajasi 95% ni tashkil etdi. Ganoderma lucidum tarkibida ACE 2 proteaza domeniga yoki SARS CoV-2 ning S-oqsiliga bog'lanib, ikki moddaning bog'lanishiga to'sqinlik qiluvchi muhim va muhim bo'lmagan ko'p miqdordagi aminokislotalar mavjud. Shunday qilib, AT1R (angiotensin II toifa I retseptorlari) faollashishi orqali o'pkaning o'tkir shikastlanishiga olib keladigan angiotensin II ning ortiqcha to'planishi yo'q. Xulosa: Ganoderma lucidum va Alxadai asosidagi yangi preparatni COVID-19 keltirib chiqaradigan koronavirus infektsiyasini davolashda qo'llash oqlanadi, chunki aminokislotalar majmuasi tufayli angiotenzin II ning ortiqcha to'planishi yo'q, bu normallashishiga olib keladi. biokimyoviy va gistologik ko'rsatkichlar
Библиографические ссылки
European Centre for Disease Prevention and Control. Threat assessment brief: emergence of SARS-CoV-2 B.1.617 variants in India and situation in the EU/EEA. May 11, 2021 (https://www.ecdc.europa.eu/en/publications- data/threat-assessment-emergence-sars-cov-2- b1617-variants. opens in new tab).
Frediansyah A. et al. Remdesivir and its antiviral activity against COVID-19: A systematic review https://doi.org/10.1016/j.cegh.2020.07.011
Gotte M. et al. Remdesivir for the treatment of COVID-19: the value of biochemical studies // Curr. Opin. Virol. - 2021.
- Vol. 49. - P. 81-85.
Hess C.B. et al. Immunomodulatory Low-Dose Whole-Lung Radiation for Patients with Coronavirus Disease 2019-Related Pneumonia // Int. J. Rad. Oncol. Biol. Phys. - 2021. - Vol. 109 (Issue 4). - Р. 867-879.
Hussien A. et al. A Clinical Review of COVID-19 // Pathogen. Diag. Manag. Bentham Sci.____________________________Publishers
https://doi.org/10.2174/1381612826666201222162509
Joint Committee on Vaccination and Immunisation. Priority groups for coronavirus (COVID-19) vaccination: advice from the JCVI, 30 December 2020. -L.: Department of Health and Social Care, 2021 (https: //www .gov.uk/government/publications/pri ority-groups-for-coronavirus-covid-19- vaccination-advice-from-the-jcvi-30-december- 2020. opens in new tab).
Ridolo E., Pucciarini F., Barone A. et al. Dermatological manifestations during COVID-19 infection: a case series and discussion on the problem of differential diagnosis // Acta Biomed. -2021. - Vol. 92, № 1. - Р. e2021103.
Rubin E.J., Baden L.R., Udwadia Z.F., Morrissey S. India’s COVID-19 crisis // New Engl. J. Med. -2021. - Vol. 384, №18. - P. e84- e84.
Schreiber G. The Role of Type I Interferons in the Pathogenesis and Treatment of COVID-19 // Front. Immunol. -2020. - Vol. 1. - P^595739.
Zheng J., Wong LY.R., Li K. et al. COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice // Nature. - 2021. - Vol. 589. - P. 603-607.
